Indole-fused spirochromenes as potential anti-tubercular agents: design, synthesis and in vitro evaluation. 2021

Ashok Dogamanti, and Pamula Chiranjeevi, and Vikas Kumar Aamate, and Siva Krishna Vagolu, and Dharmarajan Sriram, and Sridhar Balasubramanian, and Madderla Sarasija
Green and Medicinal Chemistry Lab, Department of Chemistry, Osmania University, Hyderabad, Telangana State, 500 007, India. ashokdou@gmail.com.

As part of an ongoing effort to develop new anti-tubercular agents, a series of novel indole-fused spirochromene hybrids (7a-l) were efficiently synthesized in excellent yields by the popular 'Fisher-Indole synthesis' approach. The structure elucidation of the target compounds was carried out by different spectral techniques including 1H-NMR, 13C-NMR, ESI Mass, and FTIR analysis. Additionally, the proposed structure of 7i was proved by single-crystal X-ray analysis. These compounds (7a-l) were screened for in vitro anti-tubercular activity against Mycobacterium tuberculosis H37Rv (ATCC 27294) strain. The results showed that most of the targets exhibited promising antimycobacterial activity with MICs of 1.56-6.25 μg/mL and weak cytotoxicity (19.93-32.16% at 50 μg/mL). Among them, compound 7l was found to be the most active compound (MIC of 1.56 μg/mL) with a good safety profile (32.16% at 50 μg/mL).

UI MeSH Term Description Entries
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular

Related Publications

Ashok Dogamanti, and Pamula Chiranjeevi, and Vikas Kumar Aamate, and Siva Krishna Vagolu, and Dharmarajan Sriram, and Sridhar Balasubramanian, and Madderla Sarasija
May 2018, RSC advances,
Ashok Dogamanti, and Pamula Chiranjeevi, and Vikas Kumar Aamate, and Siva Krishna Vagolu, and Dharmarajan Sriram, and Sridhar Balasubramanian, and Madderla Sarasija
February 2014, European journal of medicinal chemistry,
Ashok Dogamanti, and Pamula Chiranjeevi, and Vikas Kumar Aamate, and Siva Krishna Vagolu, and Dharmarajan Sriram, and Sridhar Balasubramanian, and Madderla Sarasija
November 2015, European journal of medicinal chemistry,
Ashok Dogamanti, and Pamula Chiranjeevi, and Vikas Kumar Aamate, and Siva Krishna Vagolu, and Dharmarajan Sriram, and Sridhar Balasubramanian, and Madderla Sarasija
February 2018, Archiv der Pharmazie,
Ashok Dogamanti, and Pamula Chiranjeevi, and Vikas Kumar Aamate, and Siva Krishna Vagolu, and Dharmarajan Sriram, and Sridhar Balasubramanian, and Madderla Sarasija
November 2001, Arzneimittel-Forschung,
Ashok Dogamanti, and Pamula Chiranjeevi, and Vikas Kumar Aamate, and Siva Krishna Vagolu, and Dharmarajan Sriram, and Sridhar Balasubramanian, and Madderla Sarasija
February 2020, RSC advances,
Ashok Dogamanti, and Pamula Chiranjeevi, and Vikas Kumar Aamate, and Siva Krishna Vagolu, and Dharmarajan Sriram, and Sridhar Balasubramanian, and Madderla Sarasija
December 2022, Chemico-biological interactions,
Ashok Dogamanti, and Pamula Chiranjeevi, and Vikas Kumar Aamate, and Siva Krishna Vagolu, and Dharmarajan Sriram, and Sridhar Balasubramanian, and Madderla Sarasija
January 2019, Medicinal chemistry (Shariqah (United Arab Emirates)),
Ashok Dogamanti, and Pamula Chiranjeevi, and Vikas Kumar Aamate, and Siva Krishna Vagolu, and Dharmarajan Sriram, and Sridhar Balasubramanian, and Madderla Sarasija
September 2013, Bioorganic & medicinal chemistry letters,
Ashok Dogamanti, and Pamula Chiranjeevi, and Vikas Kumar Aamate, and Siva Krishna Vagolu, and Dharmarajan Sriram, and Sridhar Balasubramanian, and Madderla Sarasija
August 2017, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!